Clinical Trial Update: Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib plus camrelizumab with docetaxel and S1 as first-line therapy for metastatic gastric/gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• DOCETAXEL (DOCETAXEL)
• S1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Zhou Fuxiang | Conditions: Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN